BBA
EIGR

Baker Bros. Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Baker Bros. Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,995
Closed -$4.07M – 122
2022
Q3 		$4.07M Buy
+17,995
New +$4.42M 0.03% 87
2015
Q2 		– Sell
-815
Closed -$6.95M – 131
2015
Q1 		$6.95M Sell
815
-18
-2% -$157K 0.06% 68
2014
Q4 		$7.32M Hold
833
– – 0.07% 58
2014
Q3 		$3.92M Buy
+833
New +$4.4M 0.05% 71

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Baker Bros. Advisors's EIGR Position: Q4 2022 in Review

Baker Bros. Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 17,995 shares — an estimated $4.07M sold.

Baker Bros. Advisors first reported a position in EIGR in Q3 2014 and held it in 4 quarters. The position peaked at $7.32M in Q4 2014. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Baker Bros. Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 17,995 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $4.07M.
  • Baker Bros. Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
  • Baker Bros. Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $7.32M in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.